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Cell fate is governed by combinatorial actions of
transcriptional regulators assembling into multipro-
tein complexes. However, the molecular details of
how these complexes form are poorly understood.
One such complex, which contains the basic-helix-
loop-helix heterodimer SCL:E47 and bridging pro-
teins LMO2:LDB1, critically regulates hematopoiesis
and induces T cell leukemia. Here, we report the crys-
tal structure of (SCL:E47)bHLH:LMO2:LDB1LID bound
to DNA, providing a molecular account of the
network of interactions assembling this complex.
This reveals an unexpected role for LMO2. Upon
binding to SCL, LMO2 induces new hydrogen bonds
in SCL:E47, thereby strengthening heterodimer for-
mation. This imposes a rotation movement onto
E47 that weakens the heterodimer:DNA interaction,
shifting the main DNA-binding activity onto addi-
tional protein partners. Along with biochemical
analyses, this illustrates, at an atomic level, how
hematopoietic-specific SCL sequesters ubiquitous
E47 and associated cofactors and supports
SCL’s reported DNA-binding-independent functions.
Importantly, this work will drive the design of small
molecules inhibiting leukemogenic processes.INTRODUCTION
Many, if not all, cellular processes are driven by multiprotein
complexes. In the nucleus, control of gene expression is
achieved through assembly of such molecular machines on
genomic loci in a highly controlled manner. These complexes
contain combinations of regulators such as transcription factors
(TFs), cofactors, and chromatin-remodeling proteins (Goodrich
and Tjian, 2010; Malik and Roeder, 2010) that assemble in amodular manner for rapid adaptation of gene expression pro-
grams. Although at the heart of transcription, little is known about
the molecular mechanisms driving formation of multiprotein
complexes and their interaction with DNA, the role of individual
components in this process, and the relationship between TFs
and chromatin-remodeling proteins. To address some of these
questions, we have analyzed the associations between two
evolutionarily conserved families of transcriptional regulators,
namely basic-helix-loop-helix (bHLH) and LIM domain-contain-
ing proteins (German et al., 1992; Kong et al., 1997; Lee and
Pfaff, 2003) at structural, functional, and biochemical levels.
The hematopoietic system offers a well-characterized model
to study bHLH/LIM protein interactions, such as those engaged
by the tissue-specific class II bHLH TF SCL/TAL1 (hereafter
called SCL) and the non-DNA-binding LIM-only protein LMO2.
SCL and LMO2 were initially discovered through chromosomal
translocations involved in T cell acute lymphoblastic leukemia
(T-ALL) (Begley et al., 1989; Boehm et al., 1991). Indeed, their
ectopic expression in T cell precursors occurs in up to 60%
of childhood T-ALL cases of which 80% coexpresses SCL
and LMO2 (or LMO1) (Ferrando et al., 2002, 2004). In normal
hematopoiesis, SCL and LMO2 are absolutely required for
hematopoietic specification and terminal differentiation of
specific hematopoietic lineages (Hall et al., 2003; Kassouf
et al., 2008; Le´cuyer and Hoang, 2004; Patterson et al., 2007;
Porcher et al., 1996).
SCL forms obligate heterodimers through its HLH domain
with ubiquitously expressed class I bHLH E proteins (such as
the E2A gene products, E47 and E12) (Porcher et al., 1999).
The SCL:E47 heterodimer binds through its basic regions to an
E box DNA recognition sequence (CANNTG), each monomer
recognizing one-half of the E box (Massari and Murre, 2000).
The SCL:E47 heterodimer then nucleates a ‘‘core’’ multiprotein
complex by binding to the adaptor protein LMO2 and its inter-
acting partner LDB1 (LIM-binding domain 1) (Le´cuyer and
Hoang, 2004).
The SCL core complex (SCL:E47:LMO2:LDB1) acquires
further specificity through recruitment of additional protein part-
ners. In erythroid cells, LMO2 recruits hematopoietic-specificCell Reports 4, 135–147, July 11, 2013 ª2013 The Authors 135
Table 1. Data Collection and Refinement Statistics
Data Collection Details
(SCL:E47)bHLH:LMO2:
LDB1LID:DNA (SCL:E47)bHLH:DNA
Data collection site I04 Diamond I02 Diamond
Space group F222 C2221
Cell dimensions (A˚, ) a = 102.9,
b = 141.0,
c = 148.8
a = 73.2,
b = 152.8,
c = 55.4
a = b = g = 90 a = b = g = 90
Wavelength (A˚) 1.2829 0.9795
Resolution range (A˚) 50.0–2.8 (2.9–2.8) 50.0–2.9 (3.0–2.9)
Redundancy 3.8 (2.8) 3.8 (3.7)
Completeness (%) 97.8 (95.5) 97.8 (98.5)
Average I/s (I) 11.0 (1.8) 15.6 (1.5)
Rmerge 0.086 (0.511) 0.079 (0.972)
Refinement Statistics
Resolution range (A˚) 30.15–2.80
(2.87–2.80)
42.44–2.87
(2.95–2.87)
R factor (Rwork/Rfree) 0.224/0.269 0.254/0.288
Rmsd bond length (A˚) 0.006 0.005
Rmsd bond angle () 0.9 0.8
Mean B factor (A˚2) 91.7 117.1
Ramachandran plot (%)
favored/allowed/outliers
100.0/95.5/0.0 100.0/99.3/0.0TF GATA1, creating the so-called ‘‘pentameric’’ complex that
binds a bipartite E box-GATA DNA sequence (Wadman et al.,
1997; Kassouf et al., 2010). The complex regulates expression
of important hematopoietic-specific genes (Kassouf et al.,
2010) upon recruitment of various combinations of cofactors
and chromatin remodelers, such as ETO2, mSin3A, P300,
PCAF, and LSD1 (Li et al., 2012; Schuh et al., 2005).
In T-ALL, the prevailing model suggests that ectopically ex-
pressed SCL and LMO2 synergize to prevent the activity of E
protein homodimers, essential for normal progression of T cell
differentiation. Specifically, through a sequestration mechanism
that is yet to be characterized at the molecular level, E proteins
are locked into ectopic SCL core complexes that act by repres-
sing apoptotic pathways and preventing the normal T cell
transcriptional program (Herblot et al., 2000; Palii et al., 2011;
Sanda et al., 2012).
Interestingly, for its functions in hematopoietic specification
and leukemogenesis, SCL does not rely on direct DNA-binding
activities (Draheim et al., 2011; Kassouf et al., 2008), suggesting
that it may work off DNA or be tethered to DNA through other
DNA-bound TFs. Additionally, we previously showed that
one-fifth of SCL’s genomic targets in erythroid cells can recruit
the factor independently of its DNA-binding activity (Kassouf
et al., 2010), suggesting a critical network of additional protein:
protein and protein:DNA interactions for the nucleation of such
complexes.
Despite a wealth of studies defining the SCL core complex
as a key transcriptional regulator in normal and malignant
hematopoiesis, its mechanism of action remains undefined at a
molecular level. Specifically, the molecular interactions govern-136 Cell Reports 4, 135–147, July 11, 2013 ª2013 The Authorsing protein:protein and protein:DNA associations are not
understood. Moreover, the molecular details of the E protein
sequestration model, which confers to ectopically expressed
SCL and LMO2 their oncogenic properties, are unclear. Although
functional, biochemical, and biophysical studies have suggested
potential pathways to complex assembly (Le´cuyer et al., 2007;
Ryan et al., 2008; Schlaeger et al., 2004; Wadman et al., 1997),
complete dissection of the molecular rules driving complex
formation has been hindered by the lack of a full structural
characterization. No structure exists for SCL, and whereas other
bHLH proteins and LIM proteins, including E47 (Ellenberger
et al., 1994) and LMO2 (El Omari et al., 2011), have been struc-
turally characterized, no molecular account exists of their asso-
ciation. The mechanistic role of each complex component and
their contribution to cofactor recruitment also remain unclear.
Here, we report the structure of the SCL core complex
(SCL:E47)bHLH:LMO2:LDB1LID bound to DNA. This structure,
which details a bHLH:LIM protein association, provides an
atomic description of the interactions driving the association of
the SCL:E47 heterodimer and its interface with DNA in the
presence and in absence of LMO2. Analysis of the structure un-
covers unexpected roles for SCL, E47, and LMO2. Functional
and biochemical analyses further reveal complex synergies
between components of the complex, their cofactors, and
DNA targets. Together, these results deepen our understanding
of how higher-order, hematopoietic-specific complexes form
and how tissue-specific gene expression programs might be
regulated. Importantly, the structure, which delivers insights
into the oncogenic properties of the complex, will drive the
design of small molecules for targeted inhibition of oncogenic
processes in T-ALL.
RESULTS
Overview of the Structure
The crystal structures of the (SCL:E47)bHLH heterodimer and that
of (SCL:E47)bHLH complexed to LMO2:LDB1LID, both bound to
a 11 bp blunt-ended E box DNA, were determined at 2.8 and
2.9 A˚ resolution, respectively (Table 1; Figures 1 and S1C).
DNA-bound (SCL:E47)bHLH is topologically similar to previously
reported bHLH structures, such as the (E47:E47)bHLH homo-
dimer and (E47:NeuroD1)bHLH heterodimer (Ellenberger et al.,
1994; Longo et al., 2008). The basic domains contact the major
groove of the DNA (Figure S1A), and the HLH domains,
comprising helices 1 and 2 (H1, H2) joined by a loop region,
form a parallel left-handed four-helix bundle (Figure 1A). H1 in
SCL is four amino acids shorter at its C terminus compared to
E47. The large side chain of Y235 projecting from the side of
H2 prevents formation of a longer H1 in SCL, whereas in E47,
the longer helix is accommodated by residue V595 in the same
position (Figure 1A). Because the valine and the tyrosine are
conserved residues respectively among class I and class II
bHLH proteins (Figure 1E), it is likely that the length of H1 is a
characteristic of each bHLH class. The length of H1 impacts
the length of the loop: the size and amino acid composition of
the loop are poorly conserved across different classes. On the
other hand, sequence conservation in this region between
SCL, Tal2, Lyl1, Hen1 and Hen2 (all class II proteins binding to
Figure 1. Structures of the DNA-Bound SCL:E47bHLH and SCL:E47bHLH:LMO2:LDB1LID
(A and B) Ribbon diagrams of the DNA-bound (SCL:E47)bHLH (A) and (SCL:E47)bHLH:LMO2:LDB1LID (B) structures. SCLbHLH, E47bHLH, LMO2, and LDB1LID are
colored in yellow, raspberry, green, and magenta, respectively, whereas the DNA strands are shown in blue and pink. basic, basic DNA-binding helix.
(C and D) Surface and ribbon diagram representations showing the residues involved in the HLH interface in the (SCL:E47)bHLH (C) and the (SCL:E47)bHLH:
LMO2:LDB1LID (D) structures. Hydrophobic residues are colored in orange; residues involved in hydrogen bonding in dark blue.
(E) Sequence and structural alignment of bHLH domains of SCL, E47, and other class I and class II bHLHproteins. Conserved amino acids are drawn in red boxes;
similar amino acids are in red type. Secondary structures of the bHLH domain of SCL, NeuroD1, MyoD, and E47 are depicted in yellow, light gray, dark gray, and
red, respectively. UniProtKB sequence accession numbers are P17542 (SCL), Q13562 (NEUROD1), P15172 (MYOD1), P12980 (LYL1), Q16559 (TAL2), Q02575
(HEN1), Q02577 (HEN2), P15884 (E2-2), Q99081 (HEB), and P15923 (E12 and E47). PDB accession numbers are 2YPB (SCL and E47), 2QL2 (NeuroD1), and
1MDY (MyoD).
See also Figures S1 and S2 and Table S1.
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LMO proteins; Aoyama et al., 2005; Manetopoulos et al., 2003;
Wadman et al., 1994; Figure 1E) suggests a role for the loop in
directing binding preference to LMO partner proteins.
The three-dimensional structure of DNA-bound (SCL:
E47)bHLH:LMO2:LDB1LID reveals how LMO2 binds to the bHLH
heterodimer (Figure 1B). The interactions occur almost exclu-
sively through the first LIM domain of LMO2 (LIM1), H2 of SCL
and E47, and the loop of SCL. Only two residues (R100, R102)
of the second LIM domain (LIM2) interface with (SCL:E47)bHLH.
Our previous work reporting the structure of LMO2:LDB1LID
(El Omari et al., 2011) highlighted the functional importance of
the LIM interdomain flexibility mediated through hinge residue
F88. The structure of (SCL:E47)bHLH:LMO2:LDB1LID supports
this conclusion because the LIM domains undergo a hinge
rotation around F88 to bind to (SCL:E47)bHLH (Figure S2).
The (SCL:E47)bHLH Heterodimer Interface
Interactions between bHLH proteins are driven by the strength
of their homodimeric versus heterodimeric association. The
composition of the buried hydrophobic interface of (SCL:
E47)bHLH (orange in Figure 1C; Table S1) is very similar to that
of (E47:E47)bHLH (Ellenberger et al., 1994). Sequence conserva-
tion of these hydrophobic residues across class I and II bHLH
proteins (Figure 1E) suggests structural conservation of the
HLH interface. Hydrophilic amino acids (Table S1, light-blue
residues) are also found at the bHLH interface but are less
conserved and might reflect heterodimerization specificity
between different bHLH proteins. One salt bridge and two
hydrogen bonds are formed between H2 residues from SCL
and E47 in the (SCL:E47)bHLH structure (dark-blue residues in
Figure 1C and Table S1): E247:R606, Q246:N607, and
Y235:E600, respectively. Because this latter bond is also seen
in (NeuroD1:E47)bHLH (Longo et al., 2008), it might be a common
feature of all E47 heterodimers because Y235 is conserved
among class II bHLH factors (Figure 1E). The E47 homodimer
interface contains two symmetrically positioned hydrogen
bonds between E600 of H2 from one monomer and H576 in
H1 from the other monomer (Ellenberger et al., 1994). No struc-
ture is available for the SCL homodimer, but it is very likely that,
like in the MyoD homodimer structure (Ma et al., 1994), no
hydrogen bonds are formed between monomers, a character-
istic that may decrease the stability of class II homodimers.
In our hands, SCLbHLH homodimers could not be purified in
isolation, whereas stable (SCL:E47)bHLH heterodimers could be
formed by coexpressing the two proteins; moreover, SCL homo-
dimers are not described in vivo. These results are consistent
with the view that E47:SCL is thermodynamically favored in
solution because SCL homodimers are disfavored, as previously
suggested for NeuroD1 (Longo et al., 2008). Moreover, asso-
ciation constants have been measured for (E12:E12)bHLH, (SCL:
SCL)bHLH, and (SCL:E12)bHLH with a respective KD of 7.4 3 10
4,
5.3 3 106, and 3.5 3 107 M1 (Ryan et al., 2008), in agreement
with the fact that the heterodimer is more stable than individual
homodimers. Note that E2A isoforms E47 and E12 are highly
homologous in their bHLH region and show 100% conservation
in the residues at the interface with SCL and DNA, suggesting
very similar structural and biophysical properties (see Figure 1E
and Table S1).138 Cell Reports 4, 135–147, July 11, 2013 ª2013 The AuthorsAnalysis of SCL:E47 structures in the presence of LMO2
reveals the structural impact of LMO2 on heterodimerization.
Binding of LMO2 only slightly increases the overall surface
buried in the (SCL:E47)bHLH interface (2,185 versus 2,149 A˚
2)
(Figure 1D). However, a substantial gain is seen in the network
of hydrogen bonds. Two new hydrogen bonds (Q246:V603 and
R230:D561) and one salt bridge (R230:E568) are now formed
(dark blue, Figure 1D; Table S1). Interestingly, two of these
new bonds connect H2 of SCL to H1 of E47. Salt bridges have
been implicated in the dimerization strengths and preferences
of bHLH proteins (Shirakata et al., 1993). By inducing the forma-
tion of new hydrogen bonds and salt bridges, LMO2 binding
is likely to increase the heterodimerization affinity over E47
homodimerization. Moreover, the reported in vitro association
constant of LMO2 to the heterodimer (1.8 108 M1) (Ryan
et al., 2008) is much stronger than either homo- or heterodimeric
association constants (see above), suggesting an important
function for LMO2 in ‘‘locking’’ the heterodimer structure.
Interaction of SCL:E47bHLH with DNA
(SCL:E47)bHLH is oriented on the E box motif (forward, 5
0-C1A2
G3A4T5G6-30; reverse, 50-C1*A2*T3*C4*T5*G6*-30); SCL binds the
CAG half-site and E47 the C*A*T* half-site (Figures 2A, 2B, and
S1A). Compared to other bHLH structures, (SCL:E47)bHLH
makes fewer overall contacts to DNA. The conserved glutamates
E555 (E47) and E196 (SCL) form the only specific interactions
with the DNA bases. Notably, E555 of E47 contacts the DNA
loosely, making one putative hydrogen bond to N4 of C1*
(3.6 A˚) and sitting at a distance of 3.9 A˚ from T5. The orientations
of the conserved glutamate side chains are stabilized by a salt
bridge with conserved neighboring arginines (SCL R199, E47
R558). All other interactions with DNA are through the phosphate
backbone. Four bonded contacts are formed by SCL and three
by E47 (Figure 2C). The side chains of conserved lysines at the
tip of H2 (SCL K225, E47 K585; see Figure 1A), capped by the
phosphate of C1/1*, are stabilized by a salt bridge to conserved
asparagines on H1 (SCL N204, E47 N563; see Figure 1A), sug-
gesting a bHLH canonical mechanism to anchor the position of
H1 and H2 to each other and to the DNA. All the other contacts
with the DNA backbone are nonbonded contacts.
In our structure, the (SCL:E47)bHLH heterodimer does not
directly contact the central bases of the E box motif, although
water-mediated contacts cannot be excluded at the resolution
of our structures. This is in contrast to the specific contacts
observed in the (E47:E47)bHLH:DNA structure (Ellenberger
et al., 1994). Indeed, the two E47 monomers, crystallized in the
presence of the consensus sequence for E47 (CACCTG), con-
tacted the DNA asymmetrically: the ‘‘nonspecific’’ monomer
interacted with the C*A*G* half-site through binding of E555
to the base of C1*; the ‘‘specific monomer’’ interacted with
CAC through binding of R556 to the central base G4*. In the
(SCL:E47)bHLH structure, both the E47 and the SCL basic helices
adopt the nonspecific conformation. Although a specific con-
formation is not observed in the crystal structure itself, this
does not preclude the possibility of a rotation in solution of the
E47 R556 side chain to contact the central base A4. The basic
helix of SCL appears however to be less flexible and less likely
to adopt the specific conformation (i.e., rotation of the R197
Figure 2. The DNA Recognition Interfaces
(A and B) Detailed view of SCLbHLH (A) and
E47bHLH (B) interactions in the major groove.
(C and D) Schematic diagram of detailed protein-
DNA contacts of the (SCL:E47)bHLH structure
(C) compared with the contacts of the (SCL:
E47)bHLH:LMO2:LDB1LID complex (D) using NUC-
PLOT (Luscombe et al., 1997). Hydrogen bonds
(within 3.5 A˚) are represented as thick lines to the
backbone (filled circles) or to the bases (bold
letter). van der Waals contacts (within 3.9 A˚) are
represented as thin lines.
(E) Subdomain motions of the bHLH domains
induced by LMO2 binding. Ribbon diagrams of the
DNA-bound (SCL:E47)bHLH and (SCL:E47)bHLH:
LMO2:LDB1LID structures superimposed based
on H2 of E47. The angle of rotation required to
superimpose the basic and H1 helices of E47 is
12. Color coding is yellow and gold (SCL),
raspberry and red (E47) for the (SCL:E47)bHLH
and (SCL:E47)bHLH:LMO2:LDB1LID structures,
respectively. The black rectangle corresponds to
the region shown in (F) and (G).
(F and G) Close-up views of the area around E47
residues K585 and N563, showing 2Fo  Fc
electron density maps contoured at 1 s level (gray)
and distances between residues and DNA. (F)
(SCL:E47)bHLH structure. (G) (SCL:E47)bHLH:
LMO2:LDB1LID structure. Proteins and DNA are
colored as in (E).
See also Figure S1A.side chain to contact the base of C4*). Indeed, Q201 in SCL con-
tacts the phosphate backbone at T3*, whereas the equivalent
residue in E47 (R560) does not, giving more flexibility to theCell Reports 4, 135–protein-backbone interaction (Figure 2C).
Similarly, the conserved glutamate E196
in SCL contacts the bases of C1, A2,
and T5* more closely than the equivalent
residue E555 in E47 (Figures 2A–2C),
seemingly locking SCL in its unspecific
conformation. It seems therefore likely
that if (SCL:E47)bHLH is able to bind E
boxes specifically, its orientation on
DNA is dictated by E47.
Binding of LMO2 to SCL:E47 imposes
unsuspected structural constraints
affecting heterodimer:DNA interactions.
As discussed above, binding of LMO2
tightens the heterodimerization strength
by increasing the network of hydrogen
bonds, including the creation of a salt
bridge between H2 of SCL (R230) and
H1 of E47 (E568). The creation of these
new bonds following LMO2 binding is
likely to be caused by subtle rearrange-
ments occurring to H2 of SCL, the main
interface of interaction of the heterodimer
with LMO2 (see below). The creation of
the new bonds and the subtle confor-mational changes at the heterodimer interface induce move-
ments of the H1 helices and, consequently, of the basic domains.
Specifically, the hinge angle between H1 and H2 of E47147, July 11, 2013 ª2013 The Authors 139
Figure 3. The SCL:E47bHLH:LMO2 Interface
(A and B) Surface and ribbon representation of the interface between LMO2 and, respectively, SCLbHLH (A) and E47bHLH (B). Residues found at the interface are
depicted in a stick representation. Interaction surfaces of SCL and E47 are colored in yellow and red, respectively, with overlaid electrostatic potential (blue
indicates positive; red is negative) as calculated by the program PyMOL (DeLano, 2002). See also Figure S1C.undergoes a large rotation of about 12 (Figure 2E). This causes a
shift in the bond between the conserved lysine K585 at the tip of
E47 H2 and conserved asparagine N563 in E47 H1 (Figures 2F
and 2G), a loosening of the contacts between K585 and back-
bone DNA (from 2.7 to 4.2 A˚, Figures 2D, 2F, and 2G), and a
decrease in the overall surface buried between E47 and DNA
(120 A˚2). The overall network of bonded and nonbonded con-
tacts between the LMO2-bound heterodimer and DNA de-
creases in size compared to the nonbound form (from 73 to 56
contacts). As a result, binding of LMO2 is predicted to destabilize
the (SCL:E47)bHLH:DNA interface. Of note, in vitro measurement
of the DNA-binding affinities shows that the (SCL:E12)bHLH:
LMO2:LDB1LID complex binds palindromic and nonpalindromic
E box motifs with lower affinity (between 3.7- and 1.5-fold)
than (SCL:E12)bHLH (KD = 4 3 10
5 M1 versus KD = 1.5 3 10
6
M1 for CAGCTG, and KD = 1.7 3 10
6 M1 versus KD = 2.5 3
106 M1 for CAGGTG) (Ryan et al., 2008).
Interaction of SCL:E47bHLH with LMO2:LDB1LID
Analysis of the (SCL:E47)bHLH:LMO2:LDB1LID structure defines
the SCL:LMO2 interface (Figure 3A). Despite a relatively high re-
ported association constant (Ryan et al., 2008), the SCL:LMO2
complex buries a surface area of only 1,232 A˚2, which is at the
lower end of the ‘‘standard size’’ area (1,200–2,000 A˚2) buried
in heterodimeric protein-protein complex (Lo Conte et al.,
1999). The SCL:LMO2 interaction occurs through residues
localized within a small region of their surfaces, mainly through
H2 and loop of SCL and LIM1 of LMO2 (Figure 3A), involving
an approximately equal number of hydrophobic and hydrophilic
interactions. The surface-exposed hydrophobic residues of
SCL (F238, L242, L213) and LMO2 (L59, L79, L87, F88) are the
main stabilizers of the interface, whereas two hydrogen bonds
(L213:R86, H217:C60) and a salt bridge (D245:R77) provide
specificity.
Importantly, LMO2 interacts with E47. However, the surface
area buried in this interface is very small (622 A˚2). Despite the140 Cell Reports 4, 135–147, July 11, 2013 ª2013 The Authorslimited number of hydrophobic and hydrophilic interactions
centered around residues F88 (LMO2 LIM1) and R604 (E47), a
robust salt bridge is formed between R102 (LMO2 LIM2) and
E600 (E47), which in turn forms a hydrogen bond with Y235
(SCL) (Figures 3B and S1B). A second arginine in LMO2, R100,
is also in close proximity of E600 (4.5 A˚), creating a highly
charged binding groove. Potentially, this interaction is the driving
force for the change in the SCL:E47 interface packing.
Functional Identification of the Residues Involved in the
SCL:LMO2 Interaction
To probe the relationship between the observed crystal structure
interactions and their biological role, we generated a series of
mutations predicted to perturb the interfaces between SCL,
LMO2 and E47.
We first tested the capacity of LMO2 interface mutations
(LMO2-L59G, R77A, R86A, F88D, and R100A/R102A) to bind
to wild-type (WT) SCL in two-hybrid luciferase reporter assays
(Figures 4A and S3A). The L59G mutation increased the lucif-
erase activity, suggesting that other exposed hydrophobic
residues compensate for the absence of this residue. With
R77A and R86A, luciferase activity was reduced by 60% and
80%, respectively, pointing at a specific function for the residues
mediating the hydrogen-bonding network. No activation was
observed with the F88D hinge mutant, confirming our previous
conclusions that the SCL:LMO2 interaction is strongly affected
when the rotation movement between the two LIM domains of
LMO2 is restricted (El Omari et al., 2011). Finally, the LIM2
domain mutant R100A/R102A was tested for its interaction
with SCL. R102 is the only residue of LMO2 in hydrogen bond
contact with E47; moreover, both R100 and R102 are not
conserved in other LMOs, suggesting an LMO2-specific func-
tion. Surprisingly, the mutation increased the luciferase activity,
suggesting that the function of these residues is not to provide
specificity for the interaction but, perhaps, to lock the relative
positions of LIM1 and LIM2 when binding to SCL:E47.
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Figure 4. Identification of Functionally Critical Residues at the SCL:E47:LMO2 Interface
(A and B) Luciferase-based mammalian two-hybrid assays were conducted in HEK293 cells with VP16-SCL, Gal4-LMO2, and Gal4-E47 fusion proteins. (A) WT
andmutant LMO2 proteins are coexpressed withWT SCL. (B) WT andmutant SCL proteins are coexpressed withWT E47, WT LMO2, or LMO2-L59G. Luciferase
activities resulting from interactions between WT proteins are set to 1. Error bars represent the SE from three biologically independent.experiments.
(C) Gain-of-function studies in zebrafish embryos. One-cell-stage embryos were coinjected withWT SclmRNA andWT or mutant Lmo2mRNA. Expansion of the
field of expression of the hemangioblast marker Fli1 was monitored by reverse-transcription qPCR (top) or whole-mount in situ hybridization (bottom) on
ten-somite-stage embryos (14 hpf). Error bars represent the SE from four biologically independent.experiments. Brackets indicate cardiac mesoderm; arrows
point to head mesoderm. Anterior to the top.
(D) Phenotypic rescue of hematopoiesis from Scl/ ES cells is detected using the BL-CFC assay (bottom). Blast colonies were generated upon in vitro dif-
ferentiation of WT ES cells and Scl/ ES cells untransfected () or rescued with WT or mutated versions of SCL, as indicated (top). Error bars represent the SE
from three biologically independent.experiments.
*p < 0.05; **p < 0.01.
See also Figure S3.
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To analyze the functional consequences of these mutations
in vivo, we performed gain-of-function studies in zebrafish
embryos (Gering et al., 2003). Coinjection of WT HA-Scl and
Gfp-Lmo2 mRNA leads to an expansion of Fli1-expressing
hemangioblasts (mesodermal precursors of endothelial and
hematopoietic cells) in the head, cardiac territory, and posterior
domain of the embryos (Figure 4C, bottom panel); quantitative
PCR (qPCR) at the ten-somite stage shows a 2-fold increase
in Fli1 expression levels when compared to WT embryos (Fig-
ure 4C, top panel). When expressed with WT SCL, LMO2 L59G
and R100A/R102A did not affect Fli1 expression, whereas the
mutants R77A, R86A, and F88D led to a significant reduction
in Fli1 expression when compared to WT LMO2 (Figures 4C
and S3B), in agreement with the two-hybrid assay (Figure 4A).
We then assessed the role of three residues in SCL for interac-
tion with E47 and LMO2 and for their function in hematopoietic
development. Y235, in H2, lies at the interface between SCL
and E47. H217 and F238, at the interface between SCL and
LMO2, are conserved in hematopoietic bHLH proteins (LYL1,
TAL2), but not in neuronal and muscle proteins (NeuroD1,
HEN1, HEN2, and MyoD, Figure 1E), suggesting a hematopoiet-
ic-specific function. When tested in the two-hybrid assay, inter-
action of SCL Y235A with E47 and LMO2 was greatly impaired
(Figures 4B and S3A), confirming (1) the importance of Y235
for heterodimerization, and (2) the necessity of heterodimer
formation for SCL to interact with LMO2. Individual mutations
H217A and F238A did not affect the SCL:LMO2 interaction;
however, when combined (H217A/F238A), interaction was
reduced by two-thirds. Combining SCL F238A and LMO2
L59G mutations totally abolished the interaction.
To test thesemutations functionally, we performed phenotypic
rescue assays of Scl/ ES cells. WT ES cells differentiate into
cellular structures called embryoid bodies (EBs) that contain
hematopoietic precursors giving rise to blood lineages. Using
this assay, we have previously shown that the SCL:LMO2
interaction was required for the development of primitive eryth-
ropoiesis (Schlaeger et al., 2004). In contrast, here, we assessed
the formation and development of blast colony-forming cells
(BL-CFCs or hemangioblasts), the earliest clonal ES cell-derived
mesodermal precursors of blood and endothelial cells (Choi
et al., 1998) (Figure 4D). This process requires SCL activity
(D’Souza et al., 2005); therefore, blast colonies were not ob-
served from Scl/ cells. Blast colony-forming potential was
fully rescued upon expression of a WT Scl cDNA into Scl/
ES cells (Figures 4D and S3C). The single (Y235A, F238A,
H217A) and double (F238A/H217A) mutants all abolished SCL
activity, highlighting the impact of key, single mutations on the
function of the multiprotein complex in vivo.
Altogether, these data define residues critical for formation
of a stable SCL:E47:LMO2 interface and demonstrate the
requirement for SCL heterodimerization and interaction with
LMO2 for its earliest role in hematopoietic development.
Building Higher-Order Multiprotein Complexes
In erythroid cells, the SCL core complex interacts with GATA1
and cofactors that confer transcriptional activity. In order to
understand how these higher-order complexes assemble, we
evaluated the contribution of the components of the complex142 Cell Reports 4, 135–147, July 11, 2013 ª2013 The Authorsto the recruitment of known interacting coactivators (histone
acetyltransferases PCAF and P300), corepressors (ETO2 and
histone deacetylase mSIN3A), and histone demethylase LDS1.
Guided by our structural and functional analyses, we selected
point mutations that precisely disrupt heterodimerization (SCL
Y235A) and interaction of SCL with LMO2 (SCL H217A/F238A
and LMO2 R86A); we also tested mutation of the hinge residue
in LMO2 (F88D). We expressed the corresponding mutant forms
of SCL or LMO2 as biotinylated proteins (bio-SCL or -LMO2)
in erythroid MEL cells (Schuh et al., 2005). Upon streptavidin-
affinity pull-down, copurified proteins were identified.
Members of the core complex, GATA1, and all the cofactors
tested were efficiently pulled down with WT bio-SCL (Figure 5A,
left panels, PD fraction). SCL Y235A prevented interaction with
E47 and all core members and with mSIN3A, PCAF, ETO2,
and P300, confirming that heterodimerization is essential for
SCL activity. Interestingly, interaction between SCL Y235A and
LSD1 was preserved, suggesting a different mechanism of
recruitment. The SCL H217A/F238A mutations abolished inter-
action with LMO2 and, consequently, with LDB1 and GATA1,
but not with the cofactors; their recruitment therefore does not
require interaction with LMO2 and LDB1 and is likely to occur
via the heterodimer.
WT bio-LMO2 (Figure 5A, right panels, PD fraction) efficiently
interacted with the core complex, GATA1, and the cofactors.
The R86A mutant, unable to interact with SCL and E47, retained
binding to LDB1 and GATA1, but not to the corepressors
mSin3A, ETO2, and LSD1. It could however still interact with
the coactivators PCAF and P300. When the conformational
flexibility of LMO2 was impaired (F88D), interaction with SCL
and E47 was abolished but not with LDB1 nor GATA1, indicating
that these latter interactions can occur independently of the
hinge movement and, in contrast to recent suggestions by Dast-
malchi et al. (2012), confirming that mutation of F88 does not
overall affect the structure of LMO2. mSIN3A, PCAF, ETO2,
and P300 were not able to interact with LMO2 F88D; however,
we detected an interaction with LSD1. Altogether, this suggests
that interaction of LMO2withmSin3A and ETO2 relies on binding
to the heterodimer, whereas interaction with the coactivators
can occur independently, yet it requires the hinge movement.
The LMO2:LSD1 interaction does not require SCL:E47 but only
occurs when LMO2 conformation is locked, possibly through
GATA1 and its partner FOG1 (Snow and Orkin, 2009).
DISCUSSION
This report details at the atomic and functional level the exquisite
interplay of interactions between the bHLH proteins SCL and
E47 and the LIM protein LMO2, thereby delivering mechanistic
insights into hematopoietic specification and leukemogenic
transformation. Given the importance of bHLH:LIM associations
in development and differentiation processes, this provides gen-
eral principles that will apply to other tissue-specific complexes.
LMO2 Stabilizes the SCL:E47 Association but Weakens
the Interaction of the Heterodimer with DNA
In addition to their association into heterodimers, SCL and E2A
bHLH domains can exist in vitro as homodimers (although
Figure 5. Building a Network of Interactions
between SCL:E47:LMO2:LDB1 and GATA1,
Corepressors, Coactivators, and Chro-
matin-Remodeling Proteins
(A) Multiprotein complexes containing bio-SCL
(WT, Y235A, or H217A/F238A) or bio-LMO2 (WT,
F88D, or R86A) were affinity purified fromMEL cell
nuclear extracts and analyzed by western blotting
for the presence of other members of the core
complex and known cofactors. Antibodies used
are indicated. Streptavidin-HRP was used to
detect bio-SCL or LMO2 (red-framed western
blots). MEL BirA, negative control. The asterisk (*)
indicates unspecific bands.
(B) Model representing the pentameric complex
bound to its recognition motifs (E box-GATA or 1/
2 E box-GATA; Kassouf et al., 2010) and its in-
teractions with known cofactors as suggested
by our biochemical study. The structure of the
quaternary complex bound to DNA is depicted as
in Figure 1B. The Nt portion of E47 and the acti-
vation domain AD1 are schematically represented
as a red ribbon to be able to position ETO2, P300,
PCAF, and mSin3A. See Discussion for details.
See also Figure S4.to date, only E2A homodimers have known biological func-
tions). Our results provide a structural explanation for the
hetero/homodimerization preferences and for the modulation
of these affinities upon LMO2 binding. As detailed in the Re-
sults section, we suggest that the SCL:E47 heterodimerization
interface is more stable than either individual homodimerization
interfaces and that binding of LMO2 induces subtle confor-
mational changes resulting in the creation of new hydrogen
bonds.
Furthermore, conserved hydrogen bonds, found in cis be-
tween H1 and H2 of both SCL and E47 and in trans between
SCL H2 and E47 H1, suggest a clear link between the angle of
the HLH dimerization domain and the DNA contacts available
to the basic domains. Binding of LMO2 alters the dimerization
angle and weakens the interactions between the basic helices
of SCL:E47 and DNA.
Therefore, our structural data reveal how LMO2 strengthens
the SCL:E47 interaction while weakening its association withCell Reports 4, 135–DNA. As detailed below, this provides a
powerful level of regulation of complex
formation and transcriptional activities.
Implications for Leukemogenesis
and Normal Hematopoiesis:
The Sequestration Model
Ectopic expression of oncogenic TFs in
T cell precursors causes T-ALL by inhibi-
tion of E2A:E2A target gene expression
and aberrant activation of novel targets
(Palii et al., 2011; Sanda et al., 2012).
Our work provides strong evidence for
the E2A-sequestration model in SCL-
expressing T-ALL through formation ofSCL:E2A heterodimers. Simultaneous expression of LMO2
reinforces this effect and weakens the DNA:heterodimer inter-
actions. Consequently, LMO2 binding is likely to alter expression
of E2A:E2A targets by facilitating the displacement of SCL:E2A
from DNA. The complex can then be relocated to alternative
genomic sites by association with other DNA-binding factors
such as RUNX1, ETS1, and GATA3, as recently suggested by
the reported association of SCL-binding events with Runx, Ets,
and Gata motifs in T-ALL cells (Palii et al., 2011; Sanda et al.,
2012) (Figure 6). This is corroborated by transcriptome analyses
showing expression of different gene sets in T-ALL cells upon
knockdown of SCL (Palii et al., 2011). Therefore, our structure
explains at the atomic level how ectopic expression of SCL
and LMO2 overall alters the gene repertoire in T cells to ulti-
mately lead to oncogenic transformation.
The sequestration model might also help explain the roles of
SCL and LMO2 in hematopoietic specification. Coexpression
of SCL and LMO2 in mesodermal precursors would favor147, July 11, 2013 ª2013 The Authors 143
Figure 6. Model of SCL-Mediated Network
of Interactions in Leukemogenesis and
Early and Definitive Hematopoiesis
The structural and functional data integrated
into this model are discussed in the text. The
consensus E box motifs are from Kassouf et al.
(2010), Palii et al. (2011), and Soler et al. (2010).
Although individual motifs have been reported,
composite motifs have not been described
in T cells. The DNA motifs and additional TFs
recruiting the complex in mesoderm/pre-
hematopoietic cells have not been identified. The
‘‘kinked’’ representation of SCL symbolizes its
reported DNA-binding independent activities. The
different sizes of the complexes in erythroid cells
reflect the proportion of SCL-containing binding
events on composite motifs associated with
repressed and activated target genes; for details,
see Kassouf et al. (2010).heterodimerization of E2A with SCL as opposed to other bHLH
regulators, thereby imposing a hematopoietic fate at the
expense of alternative cell fates. This agrees with recent studies
showing ectopic cardiac development in the absence of SCL
(Schoenebeck et al., 2007; Simo˜es et al., 2011; Van Handel
et al., 2012) (Figure 6).
In line with this, our phenotypic rescue of ES cell-derived
BL-CFC complemented by gain-of-function studies in zebrafish
provides a demonstration that specification of mesodermal
precursors toward the hematopoietic lineage critically depends
on the activity of a functional SCL:E47:LMO2 complex. Further
characterization will reveal some of the mechanisms underlying
the earliest stages of blood development.
Structural Basis for the DNA-Binding-Independent
Functions of SCL
Dissection of the (SCL-E47)bHLH:DNA interface shows weak
interactions with nucleic acids. This might have physiological144 Cell Reports 4, 135–147, July 11, 2013 ª2013 The Authorsrelevance, allowing fine-tuning of the ac-
tivities of SCL:E47-containing complexes
in vivo through interactions with addi-
tional DNA-bound TFs. This is also rele-
vant for the DNA-binding independent
activities of SCL in hematopoietic specifi-
cation, in leukemogenesis, and in inter-
acting with some of its erythroid genomic
targets. In red cells, LMO2 mediates
interactions of SCL:E47 with GATA1, the
complex binding a composite CANNTG-
(N)9-GATA. Amanually docked pentame-
ric complex bound to E box-GATA DNA
(Figure S4) shows that the complex can
be assembled only if the 30 amino acid
linker between the N- and C-terminal
domains of GATA1 assumes a semiex-
tended conformation. In this model, and
as dictated by the interaction of the
heterodimer with LMO2, SCL binds tothe GATA distal half-E box and E47 to the proximal one. Remark-
ably, the occurrence of a novel composite motif missing the
distal SCL-bound half-E box (CTG-(N)9-GATA) (Figure 5B) is
increased by up to 3-fold in cells expressing a DNA-binding
mutant form of SCL (Kassouf et al., 2010).
Therefore, a model emerges both in leukemia and hematopoi-
esis by which DNA-binding specificity is not driven by SCL:E47
but by its DNA-bound protein partners, the identity of which
depends upon the cellular context (Figure 6). This model
could explain the lack of interaction of SCL:E47 with the central
bases of the E box motif, in contrast to what is seen in the
(E47:E47)bHLH homodimer. Indeed, whereas we do not rule out
the possibility that binding of the specific monomer to central
bases could still be achieved in solution, the lack of interaction
observed in our crystals could alternatively be a hallmark
of bHLH heterodimers. Because recruitment of the SCL com-
plex to DNA essentially relies on interaction with LMO2 and
other DNA-binding proteins, a degenerated E box sequence
(CANNTG) would be sufficient to anchor the heterodimer to
DNA. In contrast, E47 homodimers do not bind to LMO2 and
require additional contacts with DNA for specific genomic target
recognition. Altogether, these observations refine our under-
standing of how specific binding in promoters/enhancers is
achieved and reveals an additional level of the mechanistic
diversity of TFs.
SCL Directs E47 and Main Cofactors to Hematopoietic-
Specific Targets
Our mutational and biochemical analysis uncovers a major role
for SCL in directing E47 and associated regulators to DNA (Fig-
ure 5B). The regulators ETO2, P300, PCAF, and mSin3A are
recruited to the complex by the SCL:E47 heterodimer defective
for its interaction with LMO2:LDB1, but not by the heterodimeri-
zation-defective form of SCL. This agrees with a previous report
mapping the E protein:ETO-related proteins and E protein:P300
interactions to the AD1 domain of E proteins (Zhang et al., 2004).
Similarly, PCAF, a P300-associated factor, likely interacts with
the AD1 domain. Finally, given the structural similarity of the
AD1-binding domain of ETO-related proteins (eTAFH) and the
paired amphipathic helix domain (PAH2) of mSIN3A (Plevin
et al., 2006), mSin3A also plausibly binds the AD1 domain.
Therefore, through both tissue-specific expression and inter-
action with LMO2, SCL’s main function appears to direct E47
and associated cofactors/chromatin remodelers to lineage-
restricted target genes.
In contrast, SCL interacts with LSD1 independently of its
dimerization to E47, in agreement with their described direct
association (Li et al., 2012). In this context, SCL could dimerize
with partners other than E proteins, such as HLH ID proteins
(Condorelli et al., 1995). SCL:ID complexes might regulate
transcription through formation of transient, non-DNA-binding
structures sequestering cofactors, such as LSD1, before
releasing SCL and interacting proteins for association with E47
into DNA-bound complexes.
LMO2: A Versatile Adaptor Protein
In erythroid cells, LMO2 associates with corepressors mSIN3A
and ETO2 only when in a complex with SCL:E47; therefore, not
through GATA1. This corroborates previous studies showing
that SCL repressor functions are GATA1 independent (and likely
to be mediated, at least in part, through interaction with GATA2;
Fujiwara et al., 2009), whereas the SCL:GATA1 complex is an
activator complex (Tripic et al., 2009) (Figure 6). Moreover,
GATA1 repressive complexes do not contain LMO2 (Tripic
et al., 2009) and are therefore not associated with SCL:E47.
Interestingly, the coactivators P300 and PCAF, although directly
bound to E47, can interact with LMO2 independently of its asso-
ciation with SCL:E47. Because most nuclear LMO2 is bound to
SCL (this work; Le´cuyer et al., 2007), this interaction is likely to
be mediated by another TF associated with the complex, such
as GATA1. We suggest that acetylation of GATA1 by P300 and
PCAF, described as facilitating associations with protein part-
ners and chromatin templates (Lamonica et al., 2006), plays a
critical role in the activating functions of the pentameric complex.
The hinge movement is differentially required for the LMO2
interactions with SCL:E47 and GATA1 or for its SCL-indepen-dent interaction with P300/PCAF and LSD1. This allows LMO2
to accommodate, directly or indirectly, different types of interac-
tions simultaneously, providing an extra level of regulation in
complex formation.
Therefore, LMO2 appears as a versatile adaptor protein, which
not only locks SCL:E47 structures and modulates their DNA-
binding affinities but also, through interaction with additional
regulators, plays a critical role in directing complexes to DNA.
These interactions mediate additional exposure to cofactors,
thereby modulating the transcriptional activities of the complex.
The SCL:LMO2 Interface: A Target for Small Inhibitory
Molecules
The small size of the SCL:LMO2 interface area (620 A˚2) together
with the presence of a defined secondary structure element
(SCL H2) make it a suitable target for small inhibitory molecules
(Bourgeas et al., 2010). Importantly, our mutational analyses
provide a detailed picture of key residues along the SCL:LMO2
interface required for stable and synergistic interaction. Given
the prevalence of human T-ALL cases coexpressing SCL and
LMO2, this interface emerges as a promising target for the devel-
opment of small molecules aimed at disrupting protein:protein
interactions.
EXPERIMENTAL PROCEDURES
Purification, Crystallization, and Structure Determination
LMO2:LDB1-LID construct was cloned, expressed, and purified as described
(El Omari et al., 2010). Histidine-tag SCLbHLH and untagged E47bHLH were
coexpressed in E. coli and purified by affinity and size exclusion chro-
matography. The complex was obtained by mixing LMO2:LDB1LID and
(SCL:E47)bHLH prior to size exclusion chromatography. DNA was added as
a 1.2:1 DNA-protein ratio before crystallization. Two crystal forms were ob-
tained; the first one was solved by experimental phasing to 2.8 A˚ resolution
and contained the DNA-bound (SCL:E47)bHLH:LMO2:LDB1LID. The second
one, at 2.9 A˚ resolution, was solved by molecular replacement and contained
DNA-bound (SCL:E47)bHLH. For further details, see the Extended Experimental
Procedures and Table 1.
Mammalian Two-Hybrid Assays
Plasmids encoding pVP16-SCL (VP16-transactivating domain fused to SCL)
and pM-LMO2 (GAL4 DNA-binding domain fused to LMO2) have been
described (El Omari et al., 2011; Schlaeger et al., 2004). E47 was fused to
GAL4 DNA-binding domain. All mutants were generated with a QuikChange
II Site-Directed Mutagenesis Kit (Stratagene). The CheckMate Mammalian
Two-Hybrid System (Promega) was used to conduct two-hybrid experiments
in HEK293 cells as described (El Omari et al., 2011).
LMO2-GFP Mutant Expression Constructs, RNA Injection,
Zebrafish Embryos, and Imaging
The gfp-Lmo2 construct (El Omari et al., 2011; Gering et al., 2003) wasmutated
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Full-length
Lmo2 RNAwas synthesized using the Sp6mMessage mMachine kit (Ambion).
HA-Scl/Tal1 and H2B-RFP mRNA was generated as described (El Omari
et al., 2011; Megason and Fraser, 2003). Zebrafish embryos were obtained
from natural matings and coinjected at the one-cell stage with 100 pg of
each mRNA. Embryos were raised and staged as described by Westerfield
(2007). Fluorescent signal was acquired on a Zeiss Lumar V12 fluorescence
microscope and in situ analysis carried out as described (El Omari et al.,
2011). RNA isolation and quantitative reverse-transcription PCR are described
in the Extended Experimental Procedures. The fish studies conformed to the
regulatory standards approved by UK Government Home Office.Cell Reports 4, 135–147, July 11, 2013 ª2013 The Authors 145
Biotin-Tagged Constructs
WT Scl and Lmo2 cDNAs were tagged in their 50 end with an oligonucleotide
encoding avidin-TEV-FLAG (Driegen et al., 2005) and cloned downstream of
the EF1a promoter in a vector bearing a neomycin- or zeocin-resistance
marker (pEF1abio-SCL and pEF1abio-LMO2). Mutations in Scl and Lmo2
cDNAs were generated by mutagenesis as directed by the manufacturer
(QuikChange Lightning Multi Site-Directed Mutagenesis Kit; Agilent
Technologies).
Cell Lines and Transfections
WT and Scl/ J1 ES cells were maintained on gelatinized plates as previously
described (Porcher et al., 1996). Murine erythroleukemia (MEL) cells were
maintained as described by Schuh et al. (2005). Transfection procedures are
described in the Extended Experimental Procedures.
Streptavidin-Affinity Pull-Downs
Nuclear extracts were prepared as described by Schuh et al. (2005).
Pull-downs were performed in 50 mM Tris-HCl (pH 7.5), 0.3% NP40,
150 mM NaCl, and protease inhibitors, with 500 mg to 1 mg of nuclear extracts
and 50 ml of paramagnetic streptavidin beads (Dynabeads; Invitrogen), at room
temperature for 30 min (bio-SCL) or at 4C overnight (bio-LMO2). Proteins
were eluted by boiling in Laemmli buffer. Crude nuclear extracts (input [IN]
20 mg), pull-down eluate (PD), and unbound fraction ([UN] 20 mg) were analyzed
by western blot.
ACCESSION NUMBERS
Atomic coordinates and structure factors for the (SCL:E47)bHLH:LMO2:
LDB1LID:E box and the (SCL:E47)bHLH:E box complexes have been respec-
tively deposited in the Protein Data Bank under accession numbers 2YPA
and 2YPB.
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